Stockscreener 앱 받기
31.69
2.70%
-0.88
전일 마감가:
$32.57
열려 있는:
$32.25
하루 거래량:
59,911
Relative Volume:
0.34
시가총액:
$2.09B
수익:
$282.04M
순이익/손실:
$221.88M
주가수익비율:
9.4153
EPS:
3.3658
순현금흐름:
$-449.57M
1주 성능:
+0.32%
1개월 성능:
-1.92%
6개월 성능:
+9.77%
1년 성능:
+17.46%
1일 변동 폭
$31.66
$32.49
1주일 범위
$31.41
$32.75
52주 변동 폭
$22.36
$37.78
갈라파고스 ADR Stock (GLPG) Company Profile
GLPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
31.69 | 2.15B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
갈라파고스 ADR Stock (GLPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-02-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | 다운그레이드 | Kepler | Hold → Reduce |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-08-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-08-06 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-04-20 | 개시 | Deutsche Bank | Buy |
| 2021-04-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-02-19 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | 개시 | Maxim Group | Buy |
| 2020-10-21 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-08-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-07-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-03-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-18 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | 개시 | BofA/Merrill | Neutral |
| 2019-09-09 | 재개 | Morgan Stanley | Overweight |
| 2019-07-31 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-29 | 다운그레이드 | Jefferies | Buy → Hold |
모두보기
갈라파고스 ADR 주식(GLPG)의 최신 뉴스
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025 - GlobeNewswire Inc.
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus
Operating cash flow per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Working capital per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Analysts - Defense World
EBIT per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady By Investing.com - Investing.com Canada
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
Galapagos stock rating upgraded by Leerink Partners on cost-cutting moves - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos Appoints Fred Blakeslee as General Counsel - The Globe and Mail
How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Vishay Precision Group Inc (VPG) Shares: Cheap or Risky? - fostersleader.com
Clene Inc (CLNN): What Technical Indicators Show - fostersleader.com
SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com
Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail
Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail
Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Raymond James reiterates Market Perform rating on Galapagos stock By Investing.com - Investing.com South Africa
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com
Galapagos stock holds as CEO change, spinoff plans halted By Investing.com - Investing.com India
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView
Galapagos Surges On New CEO and Upgrade News - Investing.com
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates - Benzinga
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher - Benzinga
AIM tech shares that broke America - Interactive Investor
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis - Novartis
GLPG Stock Price and Chart — NASDAQ:GLPG - TradingView — Track All Markets
Galapagos NV (GLPG) Stock Price, News, Quote & History - Yahoo! Finance Canada
갈라파고스 ADR (GLPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):